Title: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix
proteoglycan decorin in hepatocellular carcinoma
Version: 2 Date: 12 Aug 2024
Reviewer's report:
Questions To Authors And Suggestions For Rebuttal:
1. The verification of DCN expression solely in a single cell line lacks sufficient persuasiveness
without examination in other hepatocellular carcinoma (HCC) cells. Furthermore, is there any
evidence to substantiate that the HUH7 cell line is indeed an HCV-infected cell model?
2. The methodology for selecting miR-181a should be elaborated. The relevant bioinformatic
figures and analyses should be presented to support the screening process.
3. Are there plans to investigate the effects of miR-181a in animal models to corroborate the
in vitro findings?
4. Could you clarify the potential implications of your results in the context of existing treatment
options for HCC patients?
Title: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix
proteoglycan decorin in hepatocellular carcinoma
Version: 2 Date: 12 Aug 2024
Reviewer's report:
Questions To Authors And Suggestions For Rebuttal:
1. The verification of DCN expression solely in a single cell line lacks sufficient persuasiveness
without examination in other hepatocellular carcinoma (HCC) cells. Furthermore, is there any
evidence to substantiate that the HUH7 cell line is indeed an HCV-infected cell model?
2. The methodology for selecting miR-181a should be elaborated. The relevant bioinformatic
figures and analyses should be presented to support the screening process.
3. Are there plans to investigate the effects of miR-181a in animal models to corroborate the
in vitro findings?
4. Could you clarify the potential implications of your results in the context of existing treatment
options for HCC patients?
Please review this paper.
user
Title: OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix
proteoglycan decorin in hepatocellular carcinoma
Version: 2 Date: 12 Aug 2024
Reviewer's report:
Questions To Authors And Suggestions For Rebuttal:
1. The verification of DCN expression solely in a single cell line lacks sufficient persuasiveness
without examination in other hepatocellular carcinoma (HCC) cells. Furthermore, is there any
evidence to substantiate that the HUH7 cell line is indeed an HCV-infected cell model?
2. The methodology for selecting miR-181a should be elaborated. The relevant bioinformatic
figures and analyses should be presented to support the screening process.
3. Are there plans to investigate the effects of miR-181a in animal models to corroborate the
in vitro findings?
4. Could you clarify the potential implications of your results in the context of existing treatment
options for HCC patients?
assistant